{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:19Z","timestamp":1793367139909,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejso.2026.112125","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:48:34Z","timestamp":1789120114000},"page":"112125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative oncological efficacy of chemotherapy, cytoreductive surgery with or without HIPEC in recurrent ovarian cancer: A network meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-4703","authenticated-orcid":false,"given":"Richard","family":"Sassun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-2642","authenticated-orcid":false,"given":"Dario Carlo Angelo","family":"Baratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9810","authenticated-orcid":false,"given":"Marcello","family":"Guaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-836X","authenticated-orcid":false,"given":"Gaia","family":"Colletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Laura","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-4369","authenticated-orcid":false,"given":"Francesco","family":"Brucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-8891","authenticated-orcid":false,"given":"Annaclara","family":"Sileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Brescacin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-7382","authenticated-orcid":false,"given":"Tommaso","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-1395","authenticated-orcid":false,"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.112125_bib1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review [Internet]","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2026.112125_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [Internet]","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1 2","key":"10.1016\/j.ejso.2026.112125_bib3","article-title":"Ovarian cancer [Internet]","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejso.2026.112125_bib4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian cancer: sites of recurrence [Internet]","volume":"23","author":"Amate","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2026.112125_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","article-title":"Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review [Internet]","volume":"66","author":"van Baal","year":"2018","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ejso.2026.112125_bib6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae insights: Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024 [Internet]","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejso.2026.112125_bib7","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","article-title":"Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data [Internet]","volume":"24","author":"Raja","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib8","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer InterGroup [Internet]","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin [Internet]","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial [Internet]","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib11","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/cncr.33517","article-title":"Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis [Internet]","volume":"127","author":"Lee","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2026.112125_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial [Internet]","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis [Internet]","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","article-title":"Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study [Internet]","volume":"113","author":"Fagotti","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up [Internet]","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib16","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer [Internet]","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112125_bib17","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer [Internet]","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2026.112125_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","article-title":"Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial [Internet]","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.112125_bib19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial [Internet]","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a randomized trial on survival evaluation (HORSE; MITO-18) [Internet]","volume":"43","author":"Fagotti","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial [Internet]","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib22","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [Internet]","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.ejso.2026.112125_bib23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2009.08.028","article-title":"Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model [Internet]","volume":"115","author":"Jandial","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00685503","article-title":"Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy [Internet]","volume":"28","author":"Los","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejso.2026.112125_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1993.1171","article-title":"Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer [Internet]","volume":"50","author":"Markman","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib26","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1245\/s10434-023-13932-3","article-title":"The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: epithelial ovarian cancer [Internet]","volume":"30","author":"Bhatt","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib28","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials [Internet]","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.ejso.2026.112125_bib29","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II Study [Internet]","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial [Internet]","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial [Internet]","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib32","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e22","article-title":"Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study [Internet]","volume":"35","author":"Chen","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-22","article-title":"Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study [Internet]","volume":"14","author":"Van de Laar","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112125_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","article-title":"Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial [Internet]","volume":"136","author":"Lee","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib35","article-title":"Prediction models for complete resection in secondary cytoreductive surgery of patients with recurrent ovarian cancer [Internet]","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112125_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection [Internet]","volume":"19","author":"Tian","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib37","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer [Internet]","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib38","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.hoc.2025.04.018","article-title":"Surgery for recurrent ovarian cancer [Internet]","volume":"39","author":"Levy","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejso.2026.112125_bib39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41416-024-02731-6","article-title":"Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1) [Internet]","volume":"131","author":"Aronson","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2026.112125_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2020.07.017","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): should we look closer at the microenvironment? [Internet]","volume":"159","author":"Crestani","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib41","article-title":"Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer [Internet]","volume":"6","author":"Dellinger","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejso.2026.112125_bib42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00404-024-07863-x","article-title":"Secondary cytoreductive surgery in platinum-sensitive relapsed ovarian cancer: a meta-analysis of randomized controlled trials [Internet]","volume":"311","author":"Lin","year":"2025","journal-title":"Arch Gynecol Obstet"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:44:31Z","timestamp":1793364271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326007444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0748798326007444"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112125","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative oncological efficacy of chemotherapy, cytoreductive surgery with or without HIPEC in recurrent ovarian cancer: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112125"}}